Organon & Co. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Organon & Co. (OGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 7.80 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2026-02-24
- Organon & Co. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2025 was 7.80M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 12 month |
|---|---|
| 2025-12-31 | 7.80M shares 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |